Mwandishi:
Mhariri:
ULY CLINIC
Dkt. Benjamin L, MD
18 Machi 2021 18:51:29
Trimethoprim na ujauzito
Trimethoprim inayofahamika kusababisha madhaifu ya kiuumbaji kwa vichanga kwa binadamu na wanyama. Madhaifu ya kiuumbaji kwa vichanga wanaozaliwa ambayo yamekuwa yakihusiana na matumizi ya dawa hii kwa wamama wajawazito ni pamoja na madhaofu ya moyo na mfumo wa fahamu pamoja na mdomo sungura. Matumizi ya Folic acid kiasi cha miligramu 0.4 kwa siku unatakiwa kufanyika kabla ya kushika mimba ili kuzuia kutokea kwa madhaifu hayo.
Ushauri dhidi ya matumizi kwa mama mjamzito
Taarifa za binadamu (wanyama) zinaonyesha hatari ya kupata madhara
Taarifa za binadamu (wanyama) zinaonyesha hatari ya kupata madhara, ina maana gani?
Taarifa za matumizi ya dawa hii au zile zilizo kundi moja na hii au zile zinazofanana namna zinavyofanya kazi na hii kwa binadamu na wanyama wajawazito , imeonekana kuwa sumu kwenye uumbaji wa kichanga tumboni kwa na kusababisha madhaifu ya uumbaji, ukuaji, viungo vya mwili, ufanyaji kazi wa viungo, tabia au kusababisha kifo cha kichanga au kijusi tumboni katika kipindi chote cha ujauzito. Hata hivyo hatari inaweza kuvumiliwa endpo shida ya mama inahitaji dawa hii.
Ushauri wa matumizi kwa mama anayenyonyesha
Inapatana na unyonyeshaji
Inapatana na unyonyeshaji, ina maana gani?
Kiasi kidogo cha dawa hii kinawezekana kuingia kwenye maziwa ya mama, kiasi hiki hakina mashiko ya kusababisha sumu kwa kichanga anayenyonya. Dawa hii haitarajiwi kusababisha madhara kwa kichanga anayenyonya maziwa ya mama anayetumia dawa hii.
ONYO: Usitumie dawa yoyote bila ushauri wa daktari. Dawa zinaweza kuleta madhara mwilini na pia matumizi ya baadhi ya dawa pasipo ushauri na vipimo husababisha vimelea kuwa sugu dhidi ya dawa hiyo.
ULY clinic inakushauri kuwasiliana na daktari wako unapotaka kuchukua maamuzi yoyote yanayohusu afya yako.
Wasiliana na daktari/Mfamasia wa ULY clinic kwa ushauri na Tiba au kuandikiwa dawa kwa kupiga simu au Kubonyeza Pata tiba chini ya tovuti hii.
Imeboreshwa,
1 Julai 2023 17:21:36
Rejea za mada hii
1. McEwen LM. Trimethoprim/sulphamethoxazole mixture in pregnancy. Br Med J 1971;4:490–1.
2. Smithells RW. Co-trimoxazole in pregnancy. Lancet 1983;2:1142.
3. Tan JS, File TM Jr. Treatment of bacteriuria in pregnancy. Drugs 1992;44:972–80.
4. Williams JD, et al. The treatment of bacteriuria in pregnant women with sulphamethoxazole and trimethoprim. Postgrad Med J 1969;45(Suppl):71–6.
5. Ochoa AG. Trimethoprim and sulfamethoxazole in pregnancy. JAMA 1971;217:1244.
6. Brumfitt W, Pursell R. Double-blind trial to compare ampicillin, cephalexin, co-trimoxazole, and trimethoprim in treatment of urinary infection. Br Med J 1972;2:673–6.
7. Brumfitt W, Pursell R. Trimethoprim/sulfamethoxazole in the treatment of bacteriuria in women. J Infect Dis 1973;128(Suppl):S657–63.
8. Brumfitt W, Pursell R. Trimethoprim/sulfamethoxazole in the treatment of urinary infection. Med J Aust 1973;1(Suppl):44–8.
9. Bailey RR. Single-dose antibacterial treatment for bacteriuria in pregnancy. Drugs 1984;27:183–6.
10. Soper DE, Merrill-Nach S. Successful therapy of penicillinase-producing Neisseria gonorrhoeae pharyngeal infection during pregnancy. Obstet Gynecol 1986;68:290–1.
11. Cruikshank DP, Warenski JC. First-trimester maternal Listeria monocytogenes sepsis and chorioamnionitis with normal neonatal outcome. Obstet Gynecol 1989;73:469–71.
12. Seoud M, et al. Brucellosis in pregnancy. J Reprod Med 1991;36:441–5.
13. Frederiksen B. Maternal septicemia with Listeria monocytogenes in second trimester without infection of the fetus. Acta Obstet Gynecol Scand 1992;71:313–5.
14. Ronen GM. Holoprosencephaly and maternal low-calorie weight-reducing diet. Am J Med Genet 1992;42:139.
15. Richardson MP, et al. Spinal malformations in the fetuses of HIV infected women receiving combination antiretroviral therapy and co-trimoxazole. Eur J Obstet Gynecol Reprod Biol 2000;93:215–7.
16. Hernandez-Diaz S, et al. Folic acid antagonists during pregnancy and the risk of birth defects. N Engl J Med 2000;343:1608–14.
17. Hernandez-Diaz S, Mitchell AA. Folic acid antagonists during pregnancy and risk of birth defects. N Engl J Med 2001;344:934–5.
18. Hernandez-Diaz S, et al. Neural tube defects in relation to use of folic acid antagonists during pregnancy. Am J Epidemiol 2001;153:961–8.
19. Shepard TH, et al. Update on new developments in the study of human teratogens. Teratology 2002;65:153–61.
20. Czeizel AE, et al. The teratogenic risk of trimethoprim-sulfonamides: a population based case-control study. Reprod Toxicol 2001;15:637–46.
21. Product information. Septra. Monarch Pharmaceuticals, 2001.
22. Ylikorkala O, et al. Trimethoprim-sulfonamide combination administered orally and intravaginally in the 1st trimester of pregnancy: its absorption into serum and transfer to amniotic fluid. Acta Obstet Gynecol Scand 1973;52:229–34.
23. Reid DWJ, et al. Maternal and transplacental kinetics of trimethoprim and sulfamethoxazole, separately and in combination. Can Med Assoc J 1975;112:67s–72s.
24. Reeves DS, Wilkinson PJ. The pharmacokinetics of trimethoprim and trimethoprim/sulfonamide combinations, including penetration into body tissues. Infection 1979;7(Suppl 4):S330–41.
25. Bawdon RE, et al. Trimethoprim and sulfamethoxazole transfer in the in vitro perfused human cotyledon. Gynecol Obstet Invest 1991;31:240–2.
26. Koutras A, Fisher S. Niikawa-Kuroki syndrome: a new malformation syndrome of postnatal dwarfism, mental retardation, unusual face, and protruding ears. J Pediatr 1982;101:417–9.
27. Niikawa N. et al. Birth Defects Encyclopedia. Volume 2. Dover, MA: Center for Birth Defects Information Services, 1990:998–9.
28. Murdia A, et al. Sulpha-trimethoprim combinations and male fertility. Lancet 1978;2:375–6.
29. Grimmer SFM, et al. The effect of cotrimoxazole on oral contraceptive steroids in women. Contraception 1983;28:53–9.
30. Arnauld R, et al. A study of the passage of trimethoprim into the maternal milk. Quest Med 1972;25:959–64.
31. Miller RD, Salter AJ. The passage of trimethoprim/sulphamethoxazole into breast milk and its significance. In: Daikos GK, ed. Progress in Chemotherapy, Proceedings of the Eighth International Congress of Chemotherapy, Athens, 1973. Athens: Hellenic Society for Chemotherapy, 1974:687–91.
32. Ito S, et al. Prospective follow-up of adverse in breast-fed infants exposed to maternal medication. Am J Obstet Gynecol 1993;168:1393–9.
33. Committee of Drugs, American Academy of Pediatrics. The transfer of drugs and other chemicals into human milk. Pediatrics 2001;108:776–89.